|
1
|
van der Ploeg K, Kirosingh AS, Mori DAM, Chakraborty S, Hu Z, Sievers BL, Jacobson KB, Bonilla H, Parsonnet J, Andrews JR, Press KD, Ty MC, Ruiz-Betancourt DR, de la Parte L, Tan GS, Blish CA, Takahashi S, Rodriguez-Barraquer I, Greenhouse B, Singh U, Wang TT, Jagannathan P. TNF-α + CD4 + T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Rep Med 2022; 3:100640. [PMID: 35588734 PMCID: PMC9061140 DOI: 10.1016/j.xcrm.2022.100640] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 03/26/2022] [Accepted: 04/27/2022] [Indexed: 12/11/2022]
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific CD4+ T cells are likely important in immunity against coronavirus 2019 (COVID-19), but our understanding of CD4+ longitudinal dynamics following infection and of specific features that correlate with the maintenance of neutralizing antibodies remains limited. Here, we characterize SARS-CoV-2-specific CD4+ T cells in a longitudinal cohort of 109 COVID-19 outpatients enrolled during acute infection. The quality of the SARS-CoV-2-specific CD4+ response shifts from cells producing interferon gamma (IFNγ) to tumor necrosis factor alpha (TNF-α) from 5 days to 4 months post-enrollment, with IFNγ-IL-21-TNF-α+ CD4+ T cells the predominant population detected at later time points. Greater percentages of IFNγ-IL-21-TNF-α+ CD4+ T cells on day 28 correlate with SARS-CoV-2-neutralizing antibodies measured 7 months post-infection (⍴ = 0.4, p = 0.01). mRNA vaccination following SARS-CoV-2 infection boosts both IFNγ- and TNF-α-producing, spike-protein-specific CD4+ T cells. These data suggest that SARS-CoV-2-specific, TNF-α-producing CD4+ T cells may play an important role in antibody maintenance following COVID-19. SARS-CoV-2-specific CD4+ response shifts from cells producing IFNγ to TNF-α SARS-CoV-2-specific IFNγ−TNF-α+ CD4+ T cells predominate at later timepoints IFNγ-TNF-α+ CD4+ T cells correlate with durable SARS-CoV-2-neutralizing antibodies Post-infection mRNA vaccination boosts both IFNγ+ and TNF-α+ S-specific CD4+ T cells
Collapse
Affiliation(s)
- Kattria van der Ploeg
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Adam S Kirosingh
- Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Diego A M Mori
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Saborni Chakraborty
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Zicheng Hu
- Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA 94143, USA; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94143, USA
| | | | - Karen B Jacobson
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Hector Bonilla
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Julie Parsonnet
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Epidemiology and Population Health, Stanford University, Stanford, CA 94305, USA
| | - Jason R Andrews
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Kathleen D Press
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Maureen C Ty
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | | | - Lauren de la Parte
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Gene S Tan
- J. Craig Venter Institute, La Jolla, CA 92037, USA; Division of Infectious Disease, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA
| | - Catherine A Blish
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA
| | - Saki Takahashi
- Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
| | | | - Bryan Greenhouse
- Chan Zuckerberg Biohub, San Francisco, CA 94158, USA; Department of Medicine, University of California San Francisco, San Francisco, CA 94143, USA
| | - Upinder Singh
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Taia T Wang
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
| | - Prasanna Jagannathan
- Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA.
| |
Collapse
|